Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAP NASDAQ:CELU NASDAQ:ME NASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-7.6%$0.10$0.04▼$0.86$18.55M2.49128.91 million shs46.98 million shsCELUCelularity$2.07+4.0%$2.53$1.00▼$5.22$53.12M0.75214,162 shs72,585 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsZIVOZIVO Bioscience$13.33$14.49$9.97▼$22.15$51.68M-0.031,029 shs130 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-7.57%-67.67%-52.25%-81.35%-91.76%CELUCelularity+4.02%+4.55%0.00%-30.07%-9.84%ME23andMe0.00%0.00%0.00%0.00%-89.45%ZIVOZIVO Bioscience0.00%+6.52%+2.50%+20.59%-32.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAPAdaptimmune Therapeutics$0.06-7.6%$0.10$0.04▼$0.86$18.55M2.49128.91 million shs46.98 million shsCELUCelularity$2.07+4.0%$2.53$1.00▼$5.22$53.12M0.75214,162 shs72,585 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsZIVOZIVO Bioscience$13.33$14.49$9.97▼$22.15$51.68M-0.031,029 shs130 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAPAdaptimmune Therapeutics-7.57%-67.67%-52.25%-81.35%-91.76%CELUCelularity+4.02%+4.55%0.00%-30.07%-9.84%ME23andMe0.00%0.00%0.00%0.00%-89.45%ZIVOZIVO Bioscience0.00%+6.52%+2.50%+20.59%-32.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAPAdaptimmune Therapeutics 1.88Reduce$1.351,989.13% UpsideCELUCelularity 2.00Hold$6.00189.86% UpsideME23andMe 1.00SellN/AN/AZIVOZIVO Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ME, ADAP, CELU, and ZIVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ADAPAdaptimmune TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025CELUCelularityWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ADAPAdaptimmune TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CELUCelularityWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ADAPAdaptimmune TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CELUCelularityWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/9/2025CELUCelularityWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$6.008/18/2025CELUCelularityWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageModerate Buy$6.007/29/2025ADAPAdaptimmune TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/29/2025ADAPAdaptimmune TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAPAdaptimmune Therapeutics$65.09M0.26N/AN/A$0.05 per share1.29CELUCelularity$54.22M1.02N/AN/A$0.37 per share5.59ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21ZIVOZIVO Bioscience$15.85K3,260.24N/AN/A($0.81) per share-16.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAPAdaptimmune Therapeutics-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%11/12/2025 (Estimated)CELUCelularity-$57.89M-$3.18N/A∞N/A-165.22%-459.57%-57.71%11/5/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/AZIVOZIVO Bioscience-$7.78M-$2.58N/A∞N/AN/AN/A-2,240.92%11/12/2025 (Estimated)Latest ME, ADAP, CELU, and ZIVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025ADAPAdaptimmune Therapeutics-$0.09N/AN/AN/A$12.31 millionN/A8/29/2025Q1 2025CELUCelularityN/A-$1.02N/A-$1.02N/A$5.74 million8/13/2025Q2 2025ADAPAdaptimmune Therapeutics-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAPAdaptimmune TherapeuticsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAPAdaptimmune TherapeuticsN/A1.521.29CELUCelularityN/A0.250.19ME23andMeN/A1.050.91ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAPAdaptimmune Therapeutics31.37%CELUCelularity19.02%ME23andMe36.10%ZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipADAPAdaptimmune Therapeutics12.74%CELUCelularity22.10%ME23andMe26.32%ZIVOZIVO Bioscience48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAPAdaptimmune Therapeutics490265.05 million231.28 millionOptionableCELUCelularity22026.69 million20.79 millionOptionableME23andMe77026.83 million19.77 millionNot OptionableZIVOZIVO Bioscience103.88 million2.91 millionNot OptionableME, ADAP, CELU, and ZIVO HeadlinesRecent News About These CompaniesZIVO Bioscience (NASDAQ:ZIVO) Stock Crosses Below 50 Day Moving Average - Time to Sell?October 17, 2025 | marketbeat.comZIVO Bioscience releases letter to shareholdersSeptember 14, 2025 | wattagnet.comWZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comMZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comMZivo Bioscience Inc (ZIVO) USD0.001November 11, 2023 | hl.co.ukZivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72November 1, 2023 | msn.comZivo Bioscience Inc ZIVONovember 1, 2023 | morningstar.comMZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler ChickensOctober 30, 2023 | finance.yahoo.comZivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain ComplianceOctober 26, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Top 3 Dividend Achievers for October: High Yields, Growth AheadBy Thomas Hughes | October 1, 20255 Stocks Congress Quietly Bought in Q3—Should You Follow?By Thomas Hughes | October 10, 2025ME, ADAP, CELU, and ZIVO Company DescriptionsAdaptimmune Therapeutics NASDAQ:ADAP$0.06 -0.01 (-7.57%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$0.06 0.00 (-1.55%) As of 10/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Celularity NASDAQ:CELU$2.07 +0.08 (+4.02%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$2.06 -0.01 (-0.53%) As of 10/24/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.ZIVO Bioscience NASDAQ:ZIVO$13.33 0.00 (0.00%) As of 10/23/2025ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
